May 23, 2016 by Max Macaluso and Kristine HarjesDrawing Biopharma Concepts With A CrayonPeter Lynch once said, “Never invest in any idea you can’t illustrate with a crayon.” Does that hold true in the highly scientific world of biopharma?
Jun 20, 2014 by Max Macaluso and Joel SouthBetter Stock Today Challenge: InvenSense vs. SeadrillIn the spirit of World Cup competition, we’re holding our own tournament in search of the Better Stock Today.
Jun 18, 2014 by Max Macaluso and Joel SouthBetter Stock Today Challenge: InvenSense vs. DistributionNowIn the spirit of World Cup competition, we’re holding our own tournament in search of the Better Stock Today.
Jun 17, 2014 by Max Macaluso and Mark ReethBetter Stock Today Challenge: InvenSense vs. SodaStreamIn the spirit of World Cup competition, we’re holding our own tournament in search of the Better Stock Today.
Jun 17, 2014 by Max Macaluso and David HansonBetter Stock Today Challenge: Apple vs. Annaly CapitalIn the spirit of World Cup competition, we’re holding our own tournament in search of the Better Stock Today.
Jun 15, 2014 by Max Macaluso and Dave WilliamsonBetter Stock Today: InvenSense vs. Johnson & JohnsonIn the spirit of World Cup competition, we’re holding our own tournament in search of the Better Stock Today.
Jun 15, 2014 by Max Macaluso and Joel SouthBetter Stock Today: Vanguard Natural Resources vs. AppleIn the spirit of World Cup competition, we’re holding our own tournament in search of the Better Stock Today.
Jun 9, 2014 by Max Macaluso and Eric BleekerThis Internet of Things Company is Changing Medicine as We Know ItA look at smart-pill pioneer Proteus Digital Health.
Jun 5, 2014 by Max Macaluso and Eric BleekerThe Biggest Threat to Facebook's $19 Billion WhatsApp BuyWill smaller, more intimate communication networks like WhatsApp start pulling people away from sprawling ones like Facebook?
Jun 4, 2014 by Max Macaluso and Eric BleekerWill Your Car Have No Steering Wheel in 5 Years? Google Makes Its Self-Driving-Car MoveWill Google be able to get its driverless car, or at least the tech behind it, into the marketplace? Or will companies not want to play ball with the Internet giant?
Jun 4, 2014 by Max Macaluso and Eric BleekerWhy Is Intel Partnering With a Company You've Probably Never Heard Of?Tech giant Intel has partnered with the relatively unknown Rockchip in an effort to get its chips into inexpensive smartphones and tablets in emerging markets.
Jun 2, 2014 by Max Macaluso and Eric BleekerWill Google's Nest Disrupt the Smart Home Industry?Google Inc.'s Nest thermostat and ADT Corp.'s home security systems are but two of the names filling out the already crowded connected-home market.
May 31, 2014 by Max Macaluso and Eric BleekerWhat's the Future of the Connected TV?A lot of companies are developing new ways to deliver content to your TV, but will the television watching experience really change in the next few years?
May 30, 2014 by Max Macaluso and Eric BleekerAT&T Inc. Dips Its Toes in the Connected HomeAT&T Inc. is trying to connect consumers' homes with its Digital Life program, but will that in any way affect the company's bottom line?
May 28, 2014 by Max MacalusoUnderstanding Multiple Sclerosis: An Interview With Novartis' Dr. Gordon FrancisUnderstanding multiple sclerosis and Novartis' drug Gilenya.
May 20, 2014 by Max MacalusoAn Interview With Harry Kirsch, CFO of NovartisNovartis CFO Harry Kirsch discusses Novartis' culture and its recent deals with GlaxoSmithKline and Eli Lilly.
Apr 30, 2014 by Max Macaluso and Michael DouglassCannaVEST Corp.: What Investors Need to WatchWhat investors need to watch at CannaVEST
Apr 23, 2014 by Max Macaluso and Matt KoppenhefferWhat's Behind the Biotech Crash?What's the real story behind the rise and fall of the biotech bubble?
Apr 23, 2014 by Max Macaluso and Michael DouglassAllergan, Inc.: Another Billion-Dollar Buyout TargetValeant might continue its acquisition streak with the hefty purchase of Allergan.
Apr 10, 2014 by Max Macaluso and Brian Orelli, PhDBiotech Banter: FDA Delay, Clinical Trial News, and Tweet of the WeekThe latest from The Motley Fool's biotech show "Biotech Banter."
